IL-5 promotes induction of antigen-specific CD4+CD25+ T regulatory cells that suppress autoimmunity

Blood

Volumn 119, Issue 19, 2012, Pages 4441-4450

  Tran, Giang T ^a,b   Hodgkinson, Suzanne J ^a,b   Carter, Nicole M ^a,b   Verma, Nirupama D ^a   Plain, Karren M ^a   Boyd, Rochelle ^a,b   Robinson, Catherine M ^a   Nomura, Masaru ^a,b   Killingsworth, Murray ^b   Hall, Bruce M ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b LIVERPOOL HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 5 RECEPTOR ALPHA; RECOMBINANT INTERLEUKIN 5; T LYMPHOCYTE RECEPTOR BETA CHAIN; TRANSCRIPTION FACTOR FOXP3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; AUTOIMMUNITY; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DEMYELINATION; EXPERIMENTAL AUTOIMMUNE NEURITIS; FEMALE; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; LYMPHOCYTIC INFILTRATION; MACROPHAGE; NEURITIS; NONHUMAN; PARALYSIS; PARASITOSIS; PRIORITY JOURNAL; RAT; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH17 CELL; TH2 CELL; WEIGHT REDUCTION;

EID: 84861039302     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-12-396101     Document Type: Article

References (50)

1. Hall BM, Pearce NW, Gurley KE, Dorsch SE. Specific unresponsiveness in rats with prolonged cardiac allograft survival after treatment with cyclosporine, III: further characterization of the CD4+ suppressor cell and its mechanisms of action. J Exp Med. 1990;171(1):141-157. (Pubitemid 20040605)
2. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell. 2000;101(5): 455-458.
3. Verma ND, Plain KM, Nomura M, et al. CD4-CD25-T cells alloactivated ex vivo by IL-2 or IL-4, become potent alloantigen specific inhibitors of rejection with different phenotypes, suggesting Th1 and Th2 responses activate by separate pathways. Blood. 2009;113(2):479-487.
4. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha- chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995;155(3): 1151-1164.
5. Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol. 2005;6(4):345-352. (Pubitemid 41716771)
6. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299(5609):1057-1061. (Pubitemid 36222930)
7. Hall BM, Robinson CM, Plain KM, et al. Studies on naïve CD4+CD25+ T cells inhibition of naïve CD4+CD25+ T cells in mixed lymphocyte cultures. Transpl Immunol. 2008;18(4):291-300.
8. Thornton AM, Shevach EM. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med. 1998;188(2):287-296. (Pubitemid 28357757)
9. Swierkosz JE, Swanborg RH. Immunoregulation of experimental allergic encephalomyelitis: conditions for induction of suppressor cells and analysis of mechanism. Eur J Immunol. 1977;7(4): 1501-1506. (Pubitemid 8214775)
10. McCullagh P. Curtailment of autoimmunity following parabiosis with a normal partner. Immunology. 1990;71(4):595-597.
11. Smilek D, Wraith D, Hodgkinson SJ, Dwivedy S, Steinman L, McDevitt H. A single amino-acid change in a myelin-basic protein peptide confers the capacity to prevent rather than induce experimental autoimmune encephalomyelitis. Proc Natl Acad, Sci U S A. 1991;88(21):9633-9637. (Pubitemid 21915685)
12. Hall BM, Verma ND, Tran GT, Hodgkinson SJ. Distinct regulatory CD4+T cell subsets; differences between naïve and antigen specific T regulatory cells. Crit Rev Immunol. 2011;23(5):641-647.
13. Sakaguchi S. Regulatory T cells in the past and for the future. Eur J Immunol. 2008;38(4):901-937.
14. Hall BM, Jelbart ME, Gurley KE, Dorsch SE. Specific unresponsiveness in rats with prolonged cardiac allograft survival after treatment with cyclosporine. Mediation of specific suppression by T helper/inducer cells. J Exp Med. 1985;162(5): 1683-1694. (Pubitemid 16195367)
15. Hall BM, Plain KM, Verma ND, et al. Transfer of allograft-specific tolerance requires CD4+CD25+ T cells, but not IL-4 or TGF-beta and cannot induce tolerance to linked antigens. Transplantation. 2007;83(8):1075-1084. (Pubitemid 46659120)
16. Pearce NW, Spinelli A, Gurley KE, Dorsch SE, Hall BM. Mechanisms maintaining antibodyinduced enhancement of allografts, II: mediation of specific suppression by short lived CD4+ T cells. J Immunol. 1989;143(2):499-506. (Pubitemid 19191543)
17. Pearce NW, Spinelli A, Gurley KE, Hall BM. Specific unresponsiveness in rats with prolonged cardiac allograft survival after treatment with cyclosporin V. Dependence of the CD4+ suppressor cell on the presence of alloantigen and cytokines, including interleukin-2. Transplantation. 1993; 55(2):374-380. (Pubitemid 23065472)
18. Hodgkinson SJ, Westland K, Pollard JD. Transfer of experimental allergic neuritis by intraneural injection of sensitised lymphocytes. J Neurol Sci. 1994:123(1-2):162-172. (Pubitemid 24167443)
19. Tran GT, Hodgkinson SJ, Carter NM, et al. Membrane attack complex of complement is not essential for immune mediated demyelination in experimental autoimmune neuritis. J Neuroimmunol. 2010;229(1-2):98-106.
20. He XY, Verma N, Chen J, Plain K, Hall B. Cloning and expression of interleukin-5 from rats. Transplant Proc. 1999;31(3):1574-1576. (Pubitemid 29234935)
21. He XY, Verma N, Chen J, Robinson C, Boyd R, Hall BM. IL-5 prolongs allograft survival by downregulating IL-2 and IFN-gamma cytokines. Transplant Proc. 2001;33(1-2):703-704. (Pubitemid 32237583)
22. Spicer ST, Ha H, Boyd RA, et al. IL-4 therapy prevents the development of proteinuria in active Heymann nephritis by inhibition of Tc1 cells. J Immunol. 2001;167(7):3725-3733. (Pubitemid 32910817)
23. Tellides G, Dallman MJ, Morris PJ. Mechanisms of action of interleukin-2 receptor (IL-2R) monoclonal antibody (mAb) therapy: target cell depletion or inhibition of function? Transplant Proc. 1989;21(1 Pt 1):997-998. (Pubitemid 19118302)
24. Tran GT, Hodgkinson SJ, Carter N, Killingsworth M, Spicer ST, Hall BM. Attenuation of experimental allergic encephalomyelitis in complement component 6-deficient rats is associated with reduced complement C9 deposition, P-selectin expression, and cellular infiltrate in spinal cords. J Immunol. 2002;168(9):4293-4300. (Pubitemid 34441328)
25. Tran GT, Carter N, He XY, et al. Reversal of experimental allergic encephalomyelitis with nonmitogenic, non-depleting anti-CD3 mAb therapy with a preferential effect on T (h) 1 cells that is augmented by IL-4. Int Immunol. 2001;13(9): 1109-1120. (Pubitemid 32899153)
26. Hall BM, de Saxe I, Dorsch SE. The cellular basis of allograft rejection in vivo, III: restoration of firstset rejection of heart grafts by T helper cells in irradiated rats. Transplantation. 1983;36(6):700-705. (Pubitemid 14216286)
27. Penny MJ, Boyd RA, Hall BM. Role of T cells in the mediation of Heymann nephritis, II: identification of Th1 and cytotoxic cells in glomeruli. Kidney Int. 1997;51(4):1059-1068. (Pubitemid 27186531)
28. Aversa G, Waugh JA, Hall BM. A monoclonal antibody (A6) recognizing a unique epitope restricted to CD45RO and RB isoforms of the leukocyte common antigen family identifies functional T cell subsets. Cell Immunol. 1994;158(2):314-328. (Pubitemid 24344123)
29. Penny MJ, Boyd RA, Hall BM. Mycophenolate mofetil prevents the induction of active Heymann nephritis: association with Th2 cytokine inhibition. J Am Soc Nephrol. 1998;9(12):2272-2282. (Pubitemid 28543805)
30. Tran GT, Carter N, Hodgkinson SJ. Mycophenolate mofetil treatment accelerates recovery from experimental allergic encephalomyelitis. Int Immunopharmacol. 2001;1(9-10):1709-1723. (Pubitemid 32772642)
31. Spies JM, Pollard JD, Bonner JG, Westland KW, McLeod JG. Synergy between antibody and P2- reactive T cells in experimental allergic neuritis. J Neuroimmunol. 1995;57(1-2):77-84.
32. Jäger A, Dardalhon V, Sobel RA, Bettelli E, Kuchroo VK. Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes. J Immunol. 2009;183(11):7169-7177.
33. O'Garra A, Steinman L, Gijbels K. CD4+ T-cell subsets in autoimmunity. Curr Opin Immunol. 1997;9(6):872-883.
34. Rott O, Fleischer B, Cash E. Interleukin-10 prevents experimental allergic encephalomyelitis in rats. Eur J Immunol. 1994;24(6):1434-1440. (Pubitemid 24169530)
35. Zaccone P, Phillips J, Conget I, et al. Interleukin- 13 prevents autoimmune diabetes in NOD mice. Diabetes. 1999;48(8):1522-1528. (Pubitemid 29356858)
36. Mosmann TR. Role of a new cytokine, interleukin- 10, in the cross-regulation of T helper cells. Ann N Y Acad Sci. 1991;628:337-344.
37. Nakamura T, Lee RK, Nam SY, Podack ER, Bottomly K, Flavell RA. Roles of IL-4 and IFNgamma in stabilizing the T helper cell type 1 and 2 phenotype. J Immunol. 1997;158(6):2648-2653. (Pubitemid 127470521)
38. He XY, Chen J, Verma N, Plain K, Tran G, Hall BM. Treatment with interleukin-4 prolongs allogeneic neonatal heart graft survival by inducing T helper 2 responses. Transplantation. 1998; 65(9):1145-1152. (Pubitemid 28224329)
39. Davidson C, Verma ND, Robinson CM, et al. IL-13 prolongs allograft survival: association with inhibition of macrophage cytokine activation. Transpl Immunol. 2007;17(3):178-186.
40. Racke MK, Bonomo A, Scott DE, et al. Cytokineinduced immune deviation as a therapy for inflammatory autoimmune disease. J Exp Med. 1994;180(5):1961-1966. (Pubitemid 24328587)
41. Plain KM, Fava L, Spinelli A, et al. Induction of tolerance with nondepleting anti-CD4 monoclonal antibodies is associated with down regulation of Th2 cytokines. Transplantation. 1997;64(11): 1559-1567. (Pubitemid 28047383)
42. Campbell DJ, Koch MA. Phenotypical and functional specialization of FOXP3+ regulatory T cells. Nat Rev Immunol. 2011;11(2):119-130.
43. Freeman CM, Chiu BC, Stolberg VR, et al. CCR8 is expressed by antigen-elicited, IL-10-producing CD4+CD25+ T cells, which regulate Th2-mediated granuloma formation in mice. J Immunol. 2005;174(4):1962-1970. (Pubitemid 40223937)
44. Correale J, Farez M. Association between parasite infection and immune responses in multiple sclerosis. Ann Neurol. 2007;61(2):97-108. (Pubitemid 46363837)
45. Tadokoro CE, Vallochi AL, Rios LS, et al. Experimental autoimmune encephalomyelitis can be prevented and cured by infection with Trypanosoma cruzi. J Autoimmun. 2004;23(2): 103-115. (Pubitemid 39485792)
46. Summers RW, Elliott DE, Urban JFJ, Thompson RA, Weinstock JV. Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial. Gastroenterology. 2005;128(4):825-832. (Pubitemid 40523535)
47. Elliott DE, Weinstock JV. Helminthic therapy: using worms to treat immune-mediated disease. Adv Exp Med Biol. 2009;666:157-166.
48. Taylor JJ, Mohrs M, Pearce EJ. Regulatory T cell responses develop in parallel to Th responses and control the magnitude and phenotype of the Th effector population. J Immunol. 2006;176(10): 5839-5847.
49. McKee AS, Pearce EJ. CD25+CD4+ cells contribute to Th2 polarization during helminth infection by suppressing Th1 response development. J Immunol. 2004;173(2):1224-1231. (Pubitemid 38924300)
50. Jackson JA, Friberg IM, Little S, Bradley JE. Review series on helminths, immune modulation and the hygiene hypothesis: immunity against helminths and immunological phenomena in modern human populations: coevolutionary legacies? Immunology. 2009;126(1):18-27.